More recent researches also showed that treatment with brentuximab vedotin led to complete remission in patients with CD30-positive refractory extranodal NK/T-cell lymphoma [23] and cutaneous T-cell lymphoma [24]. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.